	US 11,865,091 B2
	Supporting immunomodulatory agent
Ralf Gold, Bochum (DE); Aiden Haghikia, Bochum (DE); and Ralf Linker, Uttenreuth (DE)
Assigned to Flexopharm Brain GMBH & Co. KG, Herne (DE)
Filed by Flexopharm Brain GMBH & Co. KG, Herne (DE)
Filed on Jun. 3, 2020, as Appl. No. 16/891,997.
Application 16/891,997 is a continuation of application No. 15/518,481, granted, now 10,682,322, previously published as PCT/EP2015/074179, filed on Oct. 19, 2015.
Claims priority of application No. 10 2014 015 314.2 (DE), filed on Oct. 17, 2014.
Prior Publication US 2020/0289442 A1, Sep. 17, 2020
Int. Cl. A61K 31/19 (2006.01); A23L 33/12 (2016.01); A23L 33/16 (2016.01); A61K 31/215 (2006.01); A61K 9/48 (2006.01); A61K 9/20 (2006.01); A23L 33/10 (2016.01); A23L 33/115 (2016.01); A61K 9/00 (2006.01)

CPC A61K 31/19 (2013.01) [A23L 33/10 (2016.08); A23L 33/115 (2016.08); A23L 33/12 (2016.08); A23L 33/16 (2016.08); A61K 9/0056 (2013.01); A61K 9/20 (2013.01); A61K 9/2004 (2013.01); A61K 9/48 (2013.01); A61K 9/4816 (2013.01); A61K 31/215 (2013.01); A23V 2002/00 (2013.01)]

19 Claims

1. A method of treating an immune-mediated rheumatoid disease in a subject in need thereof, comprising administering orally to said subject a composition comprising about 0.2 g to about 10 g of one or more C₃-C₈carboxylic acids, their physiologically acceptable salts and/or esters, wherein the one or more C₃-C₈carboxylic acids is propionic acid.